Core Viewpoint - MoonLake Immunotherapeutics faced a significant decline in share price following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a securities class action lawsuit alleging misleading statements about the drug's efficacy and trial design [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy of SLK being substantially lower than that of the competitor's FDA-approved product, BIMZELX [6]. - Following the announcement on September 28, 2025, MoonLake's share price plummeted by $55.75, approximately 90%, on September 29, 2025 [2][6]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK's Nanobody structure over traditional monoclonal antibodies [5][6]. - Specific allegations include misleading claims about the clinical benefits of SLK compared to BIMZELX, including the assertion that SLK would achieve superior clinical responses and could become the "gold standard" treatment [5][6]. Legal Proceedings - A securities class action has been filed against MoonLake, with a focus on the company's statements about SLK's trial design and data [1][3]. - The lead plaintiff deadline for the class action is set for December 15, 2025 [3].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data from its Phase 2 MIRA trial that suggested superior clinical responses compared to competitors [4]. - Allegations have emerged that the clinical data and the Nanobody structure of sonelokimab do not provide a superior clinical benefit over competitors, raising concerns about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 15, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against MoonLake - The complaint alleges that during the class period, the defendants made false or misleading statements and failed to disclose material facts regarding the differences between Nanobodies and monoclonal antibodies [5]. - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's Nanobody structure does not provide superior clinical benefits compared to BIMZELX [5]. - The lawsuit asserts that when the true information became public, investors suffered damages due to the misleading statements made by the defendants [5].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected shareholders between March 10, 2024, and September 29, 2025 [3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding their drug candidate SLK, asserting that it would not provide superior clinical benefits compared to BIMZELX, and that its supposed advantages in tissue penetration would not lead to clinical efficacy [4]. - The complaint highlights that the defendants lacked a reasonable basis for their positive statements about SLK's superiority over traditional monoclonal antibodies [4]. Group 2: Investor Information - Shareholders who experienced losses during the specified timeframe are encouraged to seek recovery, regardless of whether they still hold their shares [5]. - Levi & Korsinsky LLP, the firm handling the case, has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [6].

Core Points - The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a class action lawsuit for shareholders who purchased shares during the class period from March 10, 2024, to September 29, 2025 [1] - The allegations state that the defendants made materially false and misleading statements about their drug candidate SLK, claiming it had superior clinical benefits over BIMZELX, which is not supported by evidence [1] - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs and receive updates on the case [2] Company and Industry Summary - MoonLake Immunotherapeutics is facing allegations related to its drug candidate SLK, which is claimed to share molecular targets with BIMZELX and lacks a reasonable basis for claims of superiority [1] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated the company's stock [3]

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab, which led to a significant drop in stock price [1][3][7]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic aimed at treating moderate to severe hidradenitis suppurativa [4]. Group 2: Allegations and Claims - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [3]. - Allegations include that MoonLake misled investors regarding the clinical data and the Nanobody structure of sonelokimab, which purportedly did not provide a superior clinical benefit compared to competitors [5][6]. Group 3: Stock Performance and Impact - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [7].

Core Viewpoint - MoonLake Immunotherapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab, leading to significant stock price declines after disappointing trial results [2][4][5][7][8]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [5]. Group 2: Allegations and Legal Action - The lawsuit claims that MoonLake and its executives violated federal securities laws by providing misleading information about the clinical benefits of sonelokimab [2][4][6]. - The complaint is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in MoonLake common stock [4]. Group 3: Clinical Trial Results and Impact - MoonLake reported disappointing results from the VELA Phase 3 trials on September 28, 2025, with VELA-2 failing to meet its primary endpoint, raising doubts about the drug's regulatory approval and commercial viability [8]. - Following the announcement, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to a significant stock price drop [1][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. Group 3: Stock Performance Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's lack of competitive efficacy, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Viewpoint - The MoonLake class action lawsuit alleges that the company and its executives made false statements regarding the efficacy of its drug candidate, sonelokimab, leading to significant financial losses for investors [1][3][5]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's sole drug candidate, sonelokimab (SLK), is primarily aimed at treating hidradenitis suppurativa (HS) [3]. Allegations of the Lawsuit - The lawsuit claims that MoonLake and its executives failed to disclose critical information about SLK, including its molecular targets and clinical efficacy compared to Union Chimique Belge's BIMZELX [4]. - It is alleged that SLK and BIMZELX share the same molecular targets, and SLK's unique Nanobody structure does not provide a superior clinical benefit [4]. - The lawsuit highlights that SLK's supposed increased tissue penetration did not translate to improved clinical efficacy [4]. Impact of the Allegations - Following the announcement of disappointing Phase 3 trial results on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - Investors who purchased MoonLake common stock during the class period can seek to become lead plaintiffs in the lawsuit, which allows them to represent the interests of all affected investors [6]. - The deadline for filing lead plaintiff motions is December 15, 2025 [2]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases [7].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK would not lead to improved clinical efficacy, indicating that the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].